CA-VELODYNE-LIDAR
28.4.2020 14:02:06 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a three-year agreement with EasyMile, a global leader in driverless technology and smart vehicle solutions. EasyMile uses Velodyne lidar sensors in production of its EZ10 autonomous passenger shuttles that are deployed on public and private roads in more than 30 countries around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200428005241/en/
EasyMile will enhance its EZ10 shuttle fleet with Velodyne’s state-of-the-art sensors for safe and efficient navigation on roadways. Electric and driverless, the EZ10 shuttle was the one of the first autonomous shuttles launched in April 2015. It has a track record of over 200 deployments and more than 600,000 km driven in autonomous mode and one of the most advanced technology currently available. The shuttle, which has capacity for up to 15 passengers, includes a built-in automated electric ramp to support accessibility for individuals with disabilities.
“For precise navigation in real time, the EZ10s use our algorithm that fuses data from a variety of perception sensors, including lidar and camera, and localization sensors, including GPS, INS and odometry. Velodyne lidars along with radar scan for objects, vehicles, animals and people that might pose a collision threat, feeding that information to the vehicle’s control software,” explained Olivier Pairot, EasyMile’s Director of Product Marketing. “By utilizing Velodyne sensors, we are able to best gather information on every part of our environment, both close to the vehicle and at longer ranges.”
“Velodyne’s high performance lidar technology is a key component in enabling our autonomous vehicles to deliver smart mobility in urban, suburban and private environments,” said Benoit Perrin, Managing Director and COO, EasyMile. “Velodyne’s solutions have the reliability, quality and production scale we are looking for to continue to grow our fleet worldwide.”
“The EasyMile EZ10 provides a shared, inclusive driverless shuttle solution that improves public transport by connecting hubs and in many cases, delivers a transport service where there otherwise wasn’t one available,” said Erich Smidt, Executive Director Europe, Velodyne Lidar. “These shuttles show how Velodyne lidar sensors provide real-time perception data that enables safe and reliable operation for autonomous vehicles across business parks, public transport connections, university campuses and more.”
Velodyne’s sensors are optimized for outstanding indoor and outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, they can accurately detect a variety of objects.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About EasyMile
EasyMile is a global leader in driverless technology and smart vehicle solutions. The fast-growing company develops software to automate transportation platforms without the need for dedicated infrastructure. EasyMile’s cutting-edge technology is revolutionizing passenger and goods transportation, offering new mobility options. EasyMile has already deployed close to 250 driverless projects in more than 30 countries and transported people over 600,000 km. Clients include the world’s largest transport operators, city authorities, airports, corporations, business parks, and universities. Founded in 2014, EasyMile has a global presence with headquarters in Toulouse (France) and regional offices in Denver (USA), Berlin (Germany), Adelaide (Australia) and Singapore. The Company employs over 200 highly skilled and passionate employees specializing in robotics, computer vision and vehicle dynamics. Besides the two founders, CEO Gilbert Gagnaire and Board Member Philippe Ligier, EasyMile benefits from the backing of minority shareholders and strategic partners, Alstom, Continental and Bpifrance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom